Srividya Kotapati
Overview
Explore the profile of Srividya Kotapati including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
348
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Long G, Larkin J, Schadendorf D, Grob J, Lao C, Marquez-Rodas I, et al.
J Clin Oncol
. 2024 Nov;
43(8):938-948.
PMID: 39504507
Purpose: Nivolumab (NIVO) + ipilimumab (IPI) combination and NIVO monotherapy have demonstrated durable clinical benefit in patients with unresectable/metastatic melanoma. This analysis describes long-term overall survival (OS) with the combination...
2.
Baker T, Johnson H, Kotapati S, Moshyk A, Hamilton M, Kurt M, et al.
Pharmacoecon Open
. 2022 Aug;
6(5):697-710.
PMID: 36006606
Objective: The aim of this study was to evaluate the cost-utility of nivolumab plus ipilimumab (NIVO + IPI) versus other first-line therapies for advanced melanoma in the United States (US)...
3.
Samlowski W, Robert N, Chen L, Schenkel B, Davis C, Moshyk A, et al.
Cancer Med
. 2022 Jul;
12(3):2378-2388.
PMID: 35880244
Background: Nivolumab at a dose of 480 mg every 4 weeks (Q4W) is approved for the adjuvant treatment of melanoma. However, real-world data on this regimen are limited in this...
4.
Paly V, Kurt M, Zhang L, Butler M, Michielin O, Amadi A, et al.
MDM Policy Pract
. 2022 Mar;
7(1):23814683221089659.
PMID: 35356551
Background: Survival heterogeneity and limited trial follow-up present challenges for estimating lifetime benefits of oncology therapies. This study used CheckMate 067 (NCT01844505) extended follow-up data to assess the predictive accuracy...
5.
Weber J, Ascierto P, Middleton M, Hennicken D, Zoffoli R, Pieters A, et al.
Eur J Cancer
. 2021 Oct;
158:225-233.
PMID: 34663559
Background: Nivolumab (an anti-programmed death-1 antibody) is an adjuvant standard of care for patients with high-risk resected melanoma, although a watch-and-wait strategy remains an option. In the absence of head-to-head...
6.
Dalle S, Mortier L, Corrie P, Lotem M, Board R, Arance A, et al.
BMC Cancer
. 2021 May;
21(1):642.
PMID: 34051732
Background: Ipilimumab has shown long-term overall survival (OS) in patients with advanced melanoma in clinical trials, but robust real-world evidence is lacking. We present long-term outcomes from the IMAGE study...
7.
Toor K, Middleton M, Chan K, Amadi A, Moshyk A, Kotapati S
BMC Cancer
. 2021 Jan;
21(1):3.
PMID: 33402121
Background: Immune checkpoint inhibitors and targeted therapies are approved for adjuvant treatment of patients with resected melanoma; however, they have not been compared in randomized controlled trials (RCTs). We compared...
8.
Coart E, Suciu S, Squifflet P, Saad E, Moshyk A, de Schaetzen G, et al.
Eur J Cancer
. 2020 Aug;
137:171-174.
PMID: 32777716
Introduction: Recent changes in the adjuvant treatment of melanoma have raised interest in confirming relapse-free survival (RFS) as a surrogate for overall survival (OS). Methods: We explore this issue with...
9.
Hemstock M, Amadi A, Kupas K, Roskell N, Kotapati S, Gooden K, et al.
Eur J Cancer
. 2020 May;
132:176-186.
PMID: 32380428
Introduction: Until recently, adjuvant treatment options for stage III and IV resectable melanoma have been limited. Patients were often managed through routine surveillance. The phase III randomised controlled trial (RCT)...
10.
Batteson R, Hart R, Hemstock M, Gooden K, Kotapati S, Roze S, et al.
Pharmacoecon Open
. 2019 Oct;
4(2):343-351.
PMID: 31587138
Introduction: Nivolumab demonstrated significant recurrence-free survival (RFS) gains versus ipilimumab in the CheckMate-238 trial, whereas the CA184-029 trial showed superior RFS gains for ipilimumab versus placebo. No head-to-head trial data...